ElexoPharm has licensed inhibitors of the aldosterone synthase enzyme to Angion Biomedica.
Eli Lilly has completed the expansion of its biotech facility in San Diego, California. The $90 million expansion has added 180,000 square feet to the 125,000-…
Repare Therapeutics has emerged from stealth mode with an impressive $68 million.
Vineti is launching its cloud-based system to streamline company processes and accelerate patient access to cell and gene therapies.
Theranos and Walgreens have reached a tentative agreement to put the latter's breach-of-contract lawsuit to rest, WSJ sources say.
Sarepta Therapeutics has penned its second DMD gene therapy pact this year.
ImmunoCellular Therapeutics has suspended a phase 3 trial of its lead cancer vaccine after failing to raise the funds it needs to complete the study.
The FDA is working on a medical innovation development plan to lower healthcare costs by streamlining the path to market for targeted therapies.
Syntimmune has got off a beefy $50 million series B round.
Rubius Therapeutics has raised $120 million to take two of its off-the-shelf red blood cell therapies into the clinic.